Skip to content
The Intraday Markets
Pulse

Briefings

Morning BriefOvernight tape and the setup for the openMid-Morning UpdateWhat changed after the opening bell

Markets

Market DashboardTape, movers, watchlist, and cross-asset contextPre-Market SheetOvernight setup, futures, and early moversGlobal SessionsInternational clocks and index performanceInsider ActivityLatest reported executive transactions

UTHR Research

Price ChartTechnical charting and drawing workspaceFundamentals ChartCompare financial metrics across timeCompany OverviewA visual snapshot of company performanceFinancial StatementsPrice, filings, key statistics, and news

Newsletter

Morning Production ReportRanked stories, charts, and newsletter readiness

Financial Statements

Explore

Markets, briefings, and company research

UTHR
Pulse

Briefings

MorningMid-Morning

Markets

DashboardPre-MarketGlobalInsiders

UTHR Research

ChartFundamentalsOverviewFinancials

Newsletter

Morning Report

Newsletter operations and account tools are available from your profile menu after sign-in.

UTHR

$499.73
$-1.54 (-0.31%)-0.31%
After Hours
Loading chart...
IndexN/A
Market Cap21.21B
Enterprise Value20.07B
Income$0.32B
Sales$0.79B
EmployeesN/A
P/E17.88
P/S6.78
P/B3.04
P/C20.74
EV/EBITDA11.03
EV/SalesN/A
EPS (ttm)27.95
EarningsN/A
Gross Margin87.92%
Oper. Margin47.67%
Profit Margin41.94%
Volume0.45M
Shs Outstand0.04B
Change-0.31%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
Income Statement by fiscal year, newest to oldest
MetricFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Revenue$2.88B$2.33B$1.94B$1.69B$1.48B$1.45B$1.63B$1.73B
Cost of Revenue$309.70M$257.50M$146.70M$122.50M$108.10M$117.60M$198.70M$105.70M
Gross Profit$2.57B$2.07B$1.79B$1.56B$1.38B$1.33B$1.43B$1.62B
Gross Margin89.24%88.94%92.42%92.73%92.71%91.88%87.79%93.87%
Operating Expenses$1.19B$885.10M$809.90M$1.01B$781.60M$1.52B$623.70M$804.70M
Operating Income$1.38B$1.18B$979.70M$555.90M$593.60M$-187.60M$805.40M$814.90M
Operating Margin47.86%50.91%50.60%32.98%40.02%-12.95%49.48%47.23%
Net Income$1.20B$984.80M$727.30M$475.80M$514.80M$-104.50M$589.20M$417.90M
Net Margin41.53%42.31%37.56%28.23%34.71%-7.21%36.20%24.22%
EPS (Basic)$26.44$21.04$15.98$10.60$11.65$-2.39$13.54$9.50
EBITDAN/AN/AN/AN/AN/AN/AN/AN/A
Stock Option Compensation ExpenseN/AN/AN/AN/AN/AN/AN/AN/A
Price To Earnings RatioN/AN/AN/AN/AN/AN/AN/AN/A
Price To Sales RatioN/AN/AN/AN/AN/AN/AN/AN/A
Shares OutstandingN/AN/AN/AN/AN/AN/AN/AN/A
Market CapitalizationN/AN/AN/AN/AN/AN/AN/AN/A
Balance Sheet by fiscal year, newest to oldest
MetricFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Cash & Short Term InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Short Term ReceivablesN/AN/AN/AN/AN/AN/AN/AN/A
InventoriesN/AN/AN/AN/AN/AN/AN/AN/A
Other Current AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Total Current AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Net Property, Plant & EquipmentN/AN/AN/AN/AN/AN/AN/AN/A
Total Investments and AdvancesN/AN/AN/AN/AN/AN/AN/AN/A
Long-Term Note ReceivableN/AN/AN/AN/AN/AN/AN/AN/A
Intangible AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Deferred Tax AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Other AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Total Assets$7.36B$7.17B$6.04B$5.17B$4.62B$3.91B$3.40B$2.88B
Short Term Debt Incl. Current Port. of LT DebtN/AN/AN/AN/AN/AN/AN/AN/A
Accounts PayableN/AN/AN/AN/AN/AN/AN/AN/A
Income Tax PayableN/AN/AN/AN/AN/AN/AN/AN/A
Other Current LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Total Current LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Provision for Risks ChargesN/AN/AN/AN/AN/AN/AN/AN/A
Deferred Tax LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Other LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Total Liabilities$920.00M$1.18B$1.25B$1.21B$1.22B$1.13B$612.40M$777.60M
Non-Equity ReservesN/AN/AN/AN/AN/AN/AN/AN/A
Preferred Stock - Carrying ValueN/AN/AN/AN/AN/AN/AN/AN/A
Common EquityN/AN/AN/AN/AN/AN/AN/AN/A
Total Shareholders Equity$6.44B$5.98B$4.80B$3.96B$3.40B$2.78B$2.79B$2.10B
Accumulated Minority InterestN/AN/AN/AN/AN/AN/AN/AN/A
Total Equity$6.44B$5.98B$4.80B$3.96B$3.40B$2.78B$2.79B$2.10B
Total Liabilities & Stockholders Equity$7.36B$7.17B$6.04B$5.17B$4.62B$3.91B$3.40B$2.88B
Book Value Per ShareN/AN/AN/AN/AN/AN/AN/AN/A
Tangible Book Value Per ShareN/AN/AN/AN/AN/AN/AN/AN/A
Full-Time EmployeesN/AN/AN/AN/AN/AN/AN/AN/A
Price to Book RatioN/AN/AN/AN/AN/AN/AN/AN/A
Return on AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Return on EquityN/AN/AN/AN/AN/AN/AN/AN/A
Return on Invested CapitalN/AN/AN/AN/AN/AN/AN/AN/A
Quick RatioN/AN/AN/AN/AN/AN/AN/AN/A
Current RatioN/AN/AN/AN/AN/AN/AN/AN/A
Cash Flow by fiscal year, newest to oldest
MetricFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Net Income$1.20B$984.80M$727.30M$475.80M$514.80M$-104.50M$589.20M$417.90M
DepreciationN/AN/AN/AN/AN/AN/AN/AN/A
Other Funds (Non Cash)N/AN/AN/AN/AN/AN/AN/AN/A
Funds from OperationsN/AN/AN/AN/AN/AN/AN/AN/A
Extraordinary ItemN/AN/AN/AN/AN/AN/AN/AN/A
Changes in Working CapitalN/AN/AN/AN/AN/AN/AN/AN/A
Income Taxes PayableN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Operating Activities$1.33B$978.00M$802.50M$598.20M$755.70M$-206.60M$778.40M$474.20M
Capital ExpendituresN/AN/AN/AN/AN/AN/AN/AN/A
Net Assets From AcquisitionsN/AN/AN/AN/AN/AN/AN/AN/A
Sale of Fixed Assets and BusinessesN/AN/AN/AN/AN/AN/AN/AN/A
Purchase or Sale of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Purchase of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Sale Or Maturity of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Other UsesN/AN/AN/AN/AN/AN/AN/AN/A
Other SourcesN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Investing ActivitiesN/AN/AN/AN/AN/AN/AN/AN/A
Cash Dividends PaidN/AN/AN/AN/AN/AN/AN/AN/A
Change in Capital StockN/AN/AN/AN/AN/AN/AN/AN/A
Repurchase of Common Pref StockN/AN/AN/AN/AN/AN/AN/AN/A
Sale of Common Pref StockN/AN/AN/AN/AN/AN/AN/AN/A
Proceeds from Stock OptionsN/AN/AN/AN/AN/AN/AN/AN/A
Issuance or Reduction of Debt, NetN/AN/AN/AN/AN/AN/AN/AN/A
Change in Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Issuance of Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Reduction of Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Net Financing Active Other Cash FlowN/AN/AN/AN/AN/AN/AN/AN/A
Other Financing Activities UsesN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Financing ActivitiesN/AN/AN/AN/AN/AN/AN/AN/A
Exchange Rate EffectN/AN/AN/AN/AN/AN/AN/AN/A
Net Change in CashN/AN/AN/AN/AN/AN/AN/AN/A
Free Cash FlowN/AN/AN/AN/AN/AN/AN/AN/A
Preferred Dividends (Cash Flow)N/AN/AN/AN/AN/AN/AN/AN/A
Price to Free Cash FlowN/AN/AN/AN/AN/AN/AN/AN/A

Company coverage

Latest news

20 stories
Jul 28 · 9:07PMUnited Therapeutics CEO Sells $5 Million of Shares. What Does This Mean for Investors?The Motley Fool ↗Jun 30 · 4:26AMBig Pharma Has a Case of Merger ManiaThe Motley Fool ↗Jun 10 · 6:17PMiShares U.S. Pharmaceuticals ETF Tops Simplify Health Care ETF ReturnsThe Motley Fool ↗Jun 9 · 3:10PMThese 3 Stocks Lowered Their Share Counts Drastically in Q1Investing.com ↗May 19 · 5:00PMPulmonary Arterial Hypertension Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightGlobeNewswire Inc. ↗May 5 · 12:00PMTransplants.org Launches as Centralized Education and Navigation Platform for Organ and Stem Cell Transplant PatientsGlobeNewswire Inc. ↗Apr 8 · 5:00PMInterstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsightGlobeNewswire Inc. ↗Mar 30 · 4:40PMStocks Rise As Powell's Remarks Cool Rate Fears: What's Moving Markets Monday?Benzinga ↗
Show 12 more stories↓
Mar 30 · 2:08PMWhy Is United Therapeutics Stock Soaring Monday?Benzinga ↗Mar 2 · 3:32PMUnited Therapeutics' Trial Shows 55% Drop in Lung Disease WorseningBenzinga ↗Jan 26 · 1:55PMUnited Therapeutics Reports Early Success For External Liver Support In Acute FailureBenzinga ↗Jan 8 · 1:05PMMannKind Provides Business Updates and 2026 Growth DriversBenzinga ↗Dec 9 · 8:30PMWhy a $27 Million Buy Signals New Confidence in Weatherford StockThe Motley Fool ↗Dec 9 · 8:24PMSignet Jewelers Gains New $25 Million Institutional Backer — Is the Stock a Buy?The Motley Fool ↗Oct 26 · 10:31PMNepsis Liquidates $14 Million CyberArk Software (NASDAQ: CYBR) Position: Did the Stock Soar Too High, Too Fast?The Motley Fool ↗Oct 17 · 2:00PMArtificial Lung Market to Grow at 10.84% CAGR, Hits USD 7.05 Bn by 2034GlobeNewswire Inc. ↗Sep 11 · 3:12PM3 High-Growth Stocks Poised to Extend Gains Into Year-EndInvesting.com ↗Aug 6 · 2:26PMMannKind (MNKD) Q2 Revenue Rises 6%The Motley Fool ↗Jul 28 · 6:48PMROSEN, A LEADING LAW FIRM, Encourages 3D Systems Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - DDDGlobeNewswire Inc. ↗Jul 25 · 1:20AMROSEN, TOP RANKED GLOBAL COUNSEL, Encourages 3D Systems Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - DDDGlobeNewswire Inc. ↗

Insider Trading

View All
Insider
Type
Shares
Price
Value
Date
ROTHBLATT MARTINE A
Option
9.5K
$135.42
$1.3M
Aug 12, 26
ROTHBLATT MARTINE A
Option
9.5K
$135.42
$1.3M
Aug 11, 26
ROTHBLATT MARTINE A
Option
9.5K
$135.42
$1.3M
Aug 10, 26
ROTHBLATT MARTINE A
Option
9.5K
$135.42
$1.3M
Aug 7, 26
ROTHBLATT MARTINE A
Option
9.5K
$135.42
$1.3M
Aug 6, 26

Company

CEO: Martine A. RothblattEmployees: 1400www.unither.com
About the company↓

United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.

Discover more

You may be interested in
ADBE

Adobe Inc

$264.02

↓ 2.05%
JPM

JPMorgan Chase & Co

$362.84

↓ 0.25%
NVDA

NVIDIA Corp

$225.16

↓ 0.16%
INTC

Intel Corp

$102.50

↓ 1.96%
BAC

Bank of America Corp

$64.49

↑ 0.62%
NFLX

Netflix Inc

$78.16

↓ 0.08%
AMD

Advanced Micro Devices

$514.39

↑ 6.52%
MSFT

Microsoft Corp

$495.40

↓ 0.33%
CRM

Salesforce Inc

$196.21

↓ 2.42%
PYPL

PayPal Holdings Inc

$61.66

↑ 1.72%
AMZN

Amazon.com Inc

$262.65

↓ 0.95%
ABX

Abacus Global Management Inc

$9.27

↑ 8.80%
The Intraday Markets

© 2026 The Intraday. All rights reserved.

Market data may be delayedFor informational purposes onlyFMP · Massive · SEC